<PAGE>


EXHIBIT 99.1

                                     ADVANCED BIOTHERAPY, INC.
                                     6355 Topanga Canyon Boulevard, Suite 510
                                     Woodland Hills, California  91367
                                     Telephone 818-883-6716
                                     Fax           818-883-3353
                                     www.advancedbiotherapy.com
"FOR IMMEDIATE RELEASE"

  ADVANCED BIOTHERAPY, INC. DISCLOSES PATENT PENDING FOR USE OF ANTIBODIES TO
                TREAT SOLID ORGAN AND CELL TRANSPLANT REJECTION

LOS  ANGELES--August  5,  2003--Advanced  Biotherapy  Inc.  (OTCBB:ADVB  -)  - a
developer  of  new  antibody   therapies  for  treating  severe  and  widespread
autoimmune  diseases -- today announced that it has a patent application pending
for the use of antibodies to gamma  interferon  (IFN-gamma)  and tumor  necrosis
factor-alpha (TNF-alpha) and both antibodies combined for the treatment of solid
organ and cell transplant rejection.  As previously reported,  The United States
Patent and Trademark  Office  (USPTO)  issued U.S.  Patent No.  6,333,032 to the
Company for the exclusive use of IFN-gamma antibodies -- including humanized and
fully human,  as well as other antibody  types -- to treat  Multiple  Sclerosis,
Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis, Psoriatic Arthritis (a form
of psoriasis) and Ankylosing Spondylitis,  U.S. Patent No. 6,534,059 for the use
of antibodies to IFN-gamma for treating hyperimmune response in the eye (corneal
transplant  rejection),  and U.S. patent No.  5,888,511  entitled  "Treatment of
autoimmune diseases, including AIDS."

Commenting on this announcement,  Edmond  Buccellato,  the Company's CEO stated,
"There are  approximately  82,000 people waiting for a solid organ transplant in
the United  States at any one time.  Of these,  about  56,000 are  waiting for a
kidney transplant,  about 1,500 are waiting for pancreatic beta cell transplant,
about 17,000 are waiting for a liver transplant, and about 4,000 are waiting for
a heart transplant. Many individuals with serious and life-threatening illnesses
are also  waiting for bone marrow  transplants.  Approximately  2000 solid organ
transplants  are performed  each month.  The number of candidate  recipients far
outweighs the number of available organs.  After the organ has been transplanted
into the  patient  and the  patient's  immune  system is  suppressed  to prevent
rejection of the new organ, two common outcomes  frequently result. The first is
infection. If detected early, most infections can be treated with antibiotics or
other standard  therapies  along with  supportive  treatment with few or no long
term effects to the patient or  transplanted  organ.  The second  occurrence  is
rejection.  Solid organ transplant  rejection is currently prevented by matching
the donor organ with the recipient and through  immunosuppressive  therapy after
the  transplant  procedure is completed.  After the donor organ has been matched
and  implanted,   organ  transplant   recipients  must  take   immunosuppressive
medication  for the  rest of their  lives.  Initial  doses of  immunosuppressive
medications  are usually quite high,  and are  accompanied by varied and serious
side  effects.  Over  time,  the doses of  immunosuppressive  medication  can be
lowered  with  an   accompanying   decrease  in  side   effects  and   infection
susceptibility. However, the generalized immunosuppressive medications currently
in  use  are  not   without   significant   problems.   In  fact,   the  general

<PAGE>

immunosuppressants  currently  used  suppress  all  immunological  reactions  to
antigens,  either those present on the transplanted  organ or those  encountered
from infectious microbes,  tumor cells, or other disease causing anomalies,  and
overwhelming  infection  remains  the  leading  cause  of  death  in  transplant
recipients."

Mr. Buccellato  further commented,  "In a previous joint clinical  investigation
conducted  at the Research  Institute of Eye Diseases of the Russian  Academy of
Medical  Sciences,  positive  results  were  obtained  with the use of  Advanced
Biotherapy's  investigational  antibodies  in patients  suffering  from  corneal
transplant rejection  ("Treatment of Corneal Transplant Rejection in Humans with
Anti-Interferon-Gamma Antibodies," Am. J. Ophthalmology 2002; 133:829-30). As we
reported,  antibodies to interferon-gamma halted corneal transplant rejection in
all  thirteen  patients  that  were  treated.  Accordingly,  it is our view that
administration  of an effective  amount of antibody that  specifically  binds to
these cytokines is useful in alleviating, treating, or eliminating the rejection
of a solid organ or cell transplant."

About Advanced Biotherapy, Inc.
Advanced  Biotherapy,  Inc.  is  pioneering  the  development  of  new  antibody
therapies for treating severe and widespread  autoimmune diseases based on a new
understanding of the cause of these conditions.  Its  investigational  therapies
attack autoimmune  diseases at their source,  neutralizing  biologic  imbalances
that impair  immune  system  function.  Core  technology  is protected  under US
patents and patents  pending for the  exclusive  use of a class of antibodies to
the protein known as gamma  interferon  and to tumor necrosis  factor-alpha  for
treating a range of diseases.  The company is  headquartered  in Woodland Hills,
California.

Advanced  Biotherapy's antibody therapies are based on a pioneering theory first
published  nearly  three  decades ago in the  journal  Nature and later in other
scientific  journals by Simon  Skurkovich,  M.D.,  Ph.D.,  D.Sc. - the Company's
director of research and development.  Since it was first proposed,  the concept
of neutralizing the body's overproduction of certain immunomodulator  substances
to treat  autoimmune  diseases  has achieved  wide support in the  international
scientific community and has achieved commercial viability.


<PAGE>

Statements made in this news release,  other than statements of historical fact,
are forward-looking statements and are subject to a number of uncertainties that
could cause actual results to differ materially from the anticipated  results or
other expectations  expressed in our forward-looking  statements.  The risks and
uncertainties  which may affect the  development,  operations and results of our
business  include,  but are not limited to the following:  risks associated with
clinical trials, the uncertainties of research and product development programs,
the uncertainties of the regulatory  approval process,  the risks of competitive
products,  the risks of our current capital  resources,  the uncertainties as to
the availability of future capital and our future capital requirements,  and the
risks associated with the extent and breadth of the Company's patent  portfolio.
The foregoing  discussion of the pending clinical  investigations and the effect
of the patents issued and pending  involves risks and  uncertainties,  including
but not limited to the risks that third parties may be successful in challenging
such  patents;  or that  granted  claims  may be  held  invalid  or  interpreted
differently by a court of law; or that new  technologies  will be developed that
are  superior in treating  the diseases  targeted by Advanced  Biotherapy,  Inc.
Readers are cautioned not to place reliance on these forward-looking statements,
which  speak only as of the date the  statements  were made.  See the  Company's
public  filings  with  the  Securities  and  Exchange   Commission  for  further
information  about risks and  uncertainties  that may affect the Company and the
results or expectations expressed in our forward-looking  statements,  including
the section  captioned  "Factors  That May Affect The Company"  contained in the
Company's  Annual  Report on Form 10-KSB for the fiscal year ended  December 31,
2002.

CONTACT:
Advanced Biotherapy, Inc.
818/883-6716
www.advancedbiotherapy.com
SOURCE: Advanced Biotherapy, Inc.

<PAGE>

